Nanodrugs for the Treatment of Ischemic Stroke: A Systematic Review

Ruscu, Mihai Andrei; Cercel, Andreea-Mihaela; Kılıç, Ertuğrul; Cãtãlin, Bogdan; Gresita, Andrei; Hermann, Dirk M.; Albu, Carmen Valeria; Popa-Wagner, Aurel

doi:10.3390/ijms241310802

Cited by 4 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IS is also called cerebral infarction (CI), which is ischemic necrosis or cerebromalacia caused by cerebral blood supply disorders, ischemia, and hypoxia ( Ma et al, 2023 ; Ruscu et al, 2023 ; Tang et al, 2020 ). Presently, there exists no effective remedy to treat a stroke ( Barthels & Das, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

β-asarone induces viability and angiogenesis and suppresses apoptosis of human vascular endothelial cells after ischemic stroke by upregulating vascular endothelial growth factor A

Sun,

Wu,

Lan

et al. 2024

PeerJ

View full text Add to dashboard Cite

Ischemic stroke (IS) is a disease with a high mortality and disability rate worldwide, and its incidence is increasing per year. Angiogenesis after IS improves blood supply to ischemic areas, accelerating neurological recovery. β-asarone has been reported to exhibit a significant protective effect against hypoxia injury. The ability of β-asarone to improve IS injury by inducing angiogenesis has not been distinctly clarified. The experimental rats were induced with middle cerebral artery occlusion (MCAO), and oxygen-glucose deprivation (OGD) model cells were constructed using human microvascular endothelial cell line (HMEC-1) cells. Cerebral infarction and pathological damage were first determined via triphenyl tetrazolium chloride (TTC) and hematoxylin and eosin (H&E) staining. Then, cell viability, apoptosis, and angiogenesis were assessed by utilizing cell counting kit-8 (CCK-8), flow cytometry, spheroid-based angiogenesis, and tube formation assays in OGD HMEC-1 cells. Besides, angiogenesis and other related proteins were identified with western blot. The study confirms that β-asarone, like nimodipine, can ameliorate cerebral infarction and pathological damage. β-asarone can also upregulate vascular endothelial growth factor A (VEGFA) and endothelial nitric oxide synthase (eNOS) and induce phosphorylation of p38. Besides, the study proves that β-asarone can protect against IS injury by increasing the expression of VEGFA. In vitro experiments affirmed that β-asarone can induce viability and suppress apoptosis in OGD-mediated HMEC-1 cells and promote angiogenesis of OGD HMEC-1 cells by upregulating VEGFA. This establishes the potential for β-asarone to be a latent drug for IS therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

β-asarone induces viability and angiogenesis and suppresses apoptosis of human vascular endothelial cells after ischemic stroke by upregulating vascular endothelial growth factor A

Sun,

Wu,

Lan

et al. 2024

PeerJ

View full text Add to dashboard Cite

show abstract

“…MOFs display a porous structure and a significant surface area-to-volume ratio, facilitating enhanced drug loading. Their porous structure and surface modifications offer a high degree of flexibility, enabling effective targeted drug delivery and controlled release (Alkaff et al, 2020;Zenych et al, 2020;Ma et al, 2021;Yu et al, 2022b;Lin et al, 2022;Cheng et al, 2023;Ruscu et al, 2023).…”

Section: Nanomedicine Therapymentioning

confidence: 99%

Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke

Zhan,

Dai,

Ding

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Ischemic stroke (IS) refers to local brain tissue necrosis which is caused by impaired blood supply to the carotid artery or vertebrobasilar artery system. As the second leading cause of death in the world, IS has a high incidence and brings a heavy economic burden to all countries and regions because of its high disability rate. In order to effectively treat IS, a large number of drugs have been designed and developed. However, most drugs with good therapeutic effects confirmed in preclinical experiments have not been successfully applied to clinical treatment due to the low accumulation efficiency of drugs in IS areas after systematic administration. As an emerging strategy for the treatment of IS, stimuli-responsive nanomedicines have made great progress by precisely delivering drugs to the local site of IS. By response to the specific signals, stimuli-responsive nanomedicines change their particle size, shape, surface charge or structural integrity, which enables the enhanced drug delivery and controlled drug release within the IS tissue. This breakthrough approach not only enhances therapeutic efficiency but also mitigates the side effects commonly associated with thrombolytic and neuroprotective drugs. This review aims to comprehensively summarize the recent progress of stimuli-responsive nanomedicines for the treatment of IS. Furthermore, prospect is provided to look forward for the better development of this field.

show abstract

“…MOFs display a porous structure and a significant surface area-to-volume ratio, facilitating enhanced drug loading. Their porous structure and surface modifications offer a high degree of flexibility, enabling effective targeted drug delivery and controlled release (Alkaff et al, 2020;Zenych et al, 2020;Yu et al, 2022b;Lin et al, 2022;Cheng et al, 2023;Ruscu et al, 2023).…”

Section: Nanomedicine Therapymentioning

confidence: 99%

Bioactive Materials for Disease Diagnosis and Therapy

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

Nanodrugs for the Treatment of Ischemic Stroke: A Systematic Review

Cited by 4 publications

References 51 publications

β-asarone induces viability and angiogenesis and suppresses apoptosis of human vascular endothelial cells after ischemic stroke by upregulating vascular endothelial growth factor A

β-asarone induces viability and angiogenesis and suppresses apoptosis of human vascular endothelial cells after ischemic stroke by upregulating vascular endothelial growth factor A

Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke

Bioactive Materials for Disease Diagnosis and Therapy

Contact Info

Product

Resources

About